Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Toneguzzo P, Regondi V, Corsetto PA, Pietrantonio F, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, Vernieri C, Triulzi T, Pupa SM.
Castagnoli L, et al. Among authors: colombo mp.
J Exp Clin Cancer Res. 2025 May 30;44(1):165. doi: 10.1186/s13046-025-03426-3.
J Exp Clin Cancer Res. 2025.
PMID: 40442724
Free PMC article.
No abstract available.